Respiratory Virus Vaccines Market Size, Share Report And Forecast 2032

Respiratory Virus Vaccines Market Insights

According to the report published by Zion Market Research, the global Respiratory Virus Vaccines Market size was valued at USD 62.89 Billion in 2023 and is predicted to reach USD 94.70 Billion by the end of 2032. The market is expected to grow with a CAGR of 4.2% during the forecast period. The report analyzes the global Respiratory Virus Vaccines Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Respiratory Virus Vaccines industry.

Request Free Sample

Global Respiratory Virus Vaccines Market: Overview

Respiratory disorders attack the lungs or other parts of the respiratory system. Along with smoking, some of the other factors that cause respiratory disorders are air pollution, frequent occurrences of lower respiratory infection particularly among children, and constant exposure to dust & chemicals among factory workers. Lung diseases that affect the airways include cystic fibrosis, acute bronchitis – that is often caused due to exposure to viruses, chronic obstructive pulmonary disease (COPD), emphysema, and asthma. Tuberculosis, pneumonia, pneumoconiosis, pulmonary edema, and acute respiratory distress syndrome are some of the respiratory diseases affecting air sacs, or the alveoli.

Medications for each of these disorders differ and the most preferable solution is limiting the exposure to the aforementioned factors that make respiratory disorders worse. Chronic disorders such as asthma and chronic obstructive pulmonary disease have no specific treatment options, but some medications can help reduce the symptoms, stop the aggravation of the disease, and stabilize the condition of the sufferer. One of the key achievements of public health has been the protection of the general population against some respiratory infections because of vaccines. Vaccines have played a pivotal role in stopping the spread of various transmittable respiratory disorders.

Global Respiratory Virus Vaccines Market: Growth Factors

In these trying times, when respiratory disorders are causing disruptions in almost every field of human life, respiratory vaccines are more desirable then they have ever been before. According to WHO (World Health Organization), there are about 235 million asthma sufferers globally. Also, about 10 million tuberculosis cases are recorded every year, with the average death rate being 10.4% which is quite higher than several other disorders.

Till date, the United States has recorded over 16.5 million COVID-19 cases, with 6.6 million active sufferers, making it the worst affected country. The second position is taken by India, with over 9.8 million total cases recorded. Hence, a COVID-19 vaccine is the need of the hour and multiple companies are conducting extensive research and studies towards developing a COVID-19 vaccine, hence majorly affecting the global respiratory virus vaccines market positively over the forthcoming timeframe.

Additionally, there are around 200 million active sufferers of chronic obstructive pulmonary disease (COPD), with about 65 million cases being moderate or severe, with 3 million deaths per year, making COPD the third most major cause of deaths globally. Hence, the rapidly surging number of cases of chronic obstructive pulmonary disease has been a growth factor causing rapid expansion of the global respiratory virus vaccines market.

Numerous respiratory virus vaccines are in pipeline and under clinical tests. Surging amount of virus vaccines in pipelines is further predicted to stimulate the rise of the global market for respiratory virus vaccines.

However, the administrative systems and governments observe a very strict protocol for approving a particular vaccine and a number of clinical tests are done before releasing a vaccine, which may even take up to a few years. This factor is anticipated to hamper the evolution of the global respiratory virus vaccines market.

Request Free Sample

Global Respiratory Virus Vaccines Market: Segmentation

The global respiratory virus vaccines market is segregated based on vaccine, type, disease, and region.

On the basis of vaccine, the market is divided as MMR, Respiratory Syncytial Virus (RSV), DTaP, Haemophilus Influenzae Type B (Hib), and PPSV23.

Based on type, the market is classified as viral vaccine, bacterial vaccine, and combination vaccine.

By disease, the global respiratory virus vaccines market is categorized into pertussis, chronic obstructive pulmonary disease (COPD), tuberculosis, streptococcus pneumonia (pneumonia0, influenza virus, diphtheria, and others.

Respiratory Virus Vaccines Market: Report Scope

Global Respiratory Virus Vaccines Market: Regional Analysis

Asia Pacific is expected to surge at a remarkable pace over the upcoming years. This can be attributed to the well-functioning research laboratories in this region. Also, there is a high presence of respiratory disease sufferers in the region, with a large number of companies working towards developing a vaccine against disorders such as COVID-19.

North America is predicted to hold a large share of the global respiratory virus vaccines market because of complete maturation of the medical industry, heavy investments in research, favorable government policies & initiatives, fast development in the field of vaccination, higher awareness about the benefits of vaccines among the common public, and the presence of hundreds of establishments working towards developing newer and more advanced vaccines.

Global Respiratory Virus Vaccines Market: Competitive Players

The companies working in the global respiratory virus vaccines market comprise of:

• Pfizer Inc.
• Seqirus USA Inc.
• Emergent BioSolutions, Inc.
• Dr. Reddy’s Laboratories
• Bavarian Nordic
• GlaxoSmtihKline plc
• Bio Farma
• Sanofi.

The Global Respiratory Virus Vaccines Market is segmented as follows:

By vaccine 

• MMR
• Respiratory Syncytial Virus (RSV)
• DTaP
• Haemophilus Influenzae Type B (Hib)
• PPSV23

By type 

• viral vaccine
• bacterial vaccine
• combination vaccine

By disease 

• pertussis
• chronic obstructive pulmonary disease (COPD)
• tuberculosis
• streptococcus pneumonia (pneumonia0) 
• influenza virus
• diphtheria, and others

Global Respiratory Virus Vaccines Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

What Reports Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.